Trading update and progress against strategy for H1 2022
Novacyt S.A. (AIM:NCYT) Launch of monkeypox assay
Paris, France and Camberley, UK – 28 June 2022 – Novacyt ( EURONEXT GROWTH: ALNOV; AIM: NCYT ), an international specialist in clinical diagnostics, announces the launch of its research-use-only
Novacyt S.A. (AIM:NCYT) DHSC dispute update
Paris, France and Camberley, UK – 16 June 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on its ongoing dispute with
Genedrive PLC (AIM:GDR) Point-of-Care COV19-ID Kit receives CTDA approval
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the UK Medicines and Healthcare Products Regulatory Agency has granted a CTDA enabling the sale of the Genedrive®
Novacyt S.A. (AIM:NCYT) DHSC dispute update
Paris, France and Camberley, UK – 26 April 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on its ongoing dispute with
Novacyt S.A. (AIM:NCYT) Approval of COVID-19 test under CTDA legislation
Approval of second direct-to-PCR COVID-19 test in the UK under CTDA legislation
Genedrive PLC (AIM:GDR) NICE issues Medtech Innovation Briefing
NICE issues Medtech Innovation Briefing on Genedrive ® MT-RNR1 Test
Genedrive® MT-RNR1 ID Kit Product – Video
World’s first point of care genetic test used to influence neonatal management in an acute setting and reduce aminoglycoside-induced hearing loss​​
Genedrive PLC (AIM:GDR) First NHS Deployments of Genedrive System for AIHL
First NHS Deployments of the Genedrive® System for Antibiotic Induced Hearing Loss
Genedrive PLC (AIM: GDR) Update on Point of Care Covid Test
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, provides an update on the progress being made on the Genedrive®COV19-ID kit, its rapid point of care molecular test for
Novacyt S.A. (AIM: NCYT) Approval of COVID-19 test under CTDA legislation
Paris, France and Camberley, UK – 17 February 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s PROmate ® COVID-19 2G